Navigation Links
Beyond associations: Colorectal cancer culprit found
Date:4/23/2009

Genetics plays a key role in determining risk for colorectal cancer, the second leading cause of cancer-related deaths in the United States. Several common genetic markers have been found to be associated with the disease, but finding the biological events that lead to cancer can be much more difficult. In a study published online in Genome Research (www.genome.org), scientists have identified a common genetic variation associated with the risk of colorectal cancer and its functional implications, shedding new light on the basis of this deadly disease.

Hunting down the genes that underlie diseases such as colorectal cancer is extremely difficult, owing to the genetic heterogeneity of cancer cells. Numerous mutations can be found in a cancer cell, but the key to developing new treatments and therapies is to identify the variants that cause the disease hidden amongst many mutations that are simply bystanders. Recently, researchers have been aided in this search by the genome-wide association study (GWAS), a technique that scans the genome for known common genetic variants, also known as single nucleotide polymorphisms, or "SNPs," that are more prevalent in patients with a specific disease. However, a SNP associated with a disease is not necessarily the culprit but it raises a red flag that something important is nearby.

In this study, an international team of researchers led by Dr. Richard Houlston of The Institute of Cancer Research in the United Kingdom have delved into the biology underlying common variants on chromosome 18 that his group recently found to be associated with colorectal cancer in a GWAS. They sequenced the region of DNA surrounding these markers in a large group of colorectal cancer cases and controls, identifying all variants residing in this chromosomal region common to colorectal cancer patients.

Houlston and colleagues then focused on the novel variant most strongly associated with colorectal cancer, and found that it resides in a DNA sequence that is conserved in many other species so well conserved that they were able to use xenopus frogs as a model organism to test the biological consequences of this SNP. The group found that the SNP causes the expression of a nearby gene, called SMAD7, to decrease. SMAD7 is an inhibitory regulator of TGF-beta signaling. If cellular levels of SMAD7 are down, critical signaling events could be set into motion, leading the cell on the path to cancer. This result is particularly important because disruption of SMAD7 expression has been previously implicated in progression of colorectal cancer. Taken together with this knowledge, their observation supports a direct role for SMAD7 in cancer progression, and very likely the causal basis for colorectal cancer risk associated with this chromosomal region.

Houlston explained, "Our efforts show that many different methodologies are required to close in and identify disease-causing variants identified through genome-wide association studies." Their work specifically exemplifies the combination of genetic and functional analyses, including regenotyping, resequencing, and use of model organisms, needed to approach the biological mechanism of cancer. By identifying the true causal variants and understanding the biological basis for cancer risk associated with those variants, researchers will be able to design better screening strategies and more effective therapies for patients.


'/>"/>

Contact: Peggy Calicchia
calicchi@cshl.edu
516-422-4012
Cold Spring Harbor Laboratory
Source:Eurekalert

Related biology technology :

1. Out beyond the horizon
2. Out beyond the horizon
3. Stem Cell Science Holds Opportunities as Important Tool for Diabetes Research Beyond Cell-Based Treatments
4. Beyond DTC: Pharma Industry Faces New Challenges, Competition, Strategies for Market Dominance
5. Symmetry Medical Extends 10-K Filing Beyond April 14, 2008 Target
6. WaferGen to Present at the Ninth Annual Beyond Genome Conference
7. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
8. Far From Beyond: A Glimpse into the World of Biotechnology and the Future of the Free World
9. Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM)
10. Dow AgroSciences Delivering Beyond Expectations
11. Informex Survey Shows Innovation Remains a Priority for 2009 and Beyond
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV), a precision medicine ... Bill Welch , will be presenting at this ... AM EDT at the Essex House in ... Scientific Officer, Mark Erlander , Ph.D., will also ... The presentation will be webcast live at ...
(Date:3/27/2017)... 2017 Neurotrope, Inc. (OTCQB: NTRP),  a ... diseases, including Alzheimer,s disease, today announced that it ... the Company,s common stock on the NASDAQ Capital ... Market, a unit of the NASDAQ OMX Group. ... Opening Bell at the NASDAQ MarketSite in Times ...
(Date:3/24/2017)... and ROCKVILLE, Md. , ... company of Maxwell Biotech Venture Fund (MBVF), today announced ... SQ109 added to the standard drug therapy regimen in ... new small molecule drug discovered by scientists at Sequella, ... National Institutes of Health. A total ...
(Date:3/24/2017)... BEIJING , March 24, 2017 Sinovac Biotech Ltd. ... products in China , today announced that its ... the expiration date of the plan from March 27, 2017 to ... proposal. About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is ...
Breaking Biology Technology:
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
(Date:2/22/2017)... , Feb. 22, 2017 With the ... ABI Research identifies four technologies that innovative and ... secure significant share in the changing competitive landscape: ... passive authentication.   "Companies can no ... to security," says Dimitrios Pavlakis , Industry ...
Breaking Biology News(10 mins):